echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Nuocheng Jianhua's new TYK2 inhibitor ICP-332 completes the first subject administration

    Nuocheng Jianhua's new TYK2 inhibitor ICP-332 completes the first subject administration

    • Last Update: 2021-08-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 16, Nuocheng Jianhua announced that the company's self-developed new tyrosine kinase 2 (Tyrosine Kinase 2, TYK2) inhibitor ICP-332 has completed the first subject administration in China


    ICP-332 is a class 1 innovative drug with global independent intellectual property rights of Nuocheng Jianhua, and it is a new type of oral TYK2 inhibitor


    As a highly selective new TYK2 inhibitor, ICP-332 has a strong inhibitory activity on TYK2, with a selectivity of about 400 times for JAK2, which can reduce the adverse effects of anemia due to JAK2 inhibition


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.